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ABSTRACT
The potential of autologous cell-based therapies including those using multipotent mesenchymal
stromal cells (MSCs) is being investigated for multiple sclerosis (MS) and other neurological con-
ditions. However, the phenotype of MSC in neurological diseases has not been fully character-
ized. We have previously shown that MSC isolated from patients with progressive MS (MS-MSC)
have reduced expansion potential, premature senescence, and reduced neuroprotective poten-
tial in vitro. In view of the role of antioxidants in ageing and neuroprotection, we examined the
antioxidant capacity of MS-MSC demonstrating that MS-MSC secretion of antioxidants superox-
ide dismutase 1 (SOD1) and glutathione S-transferase P (GSTP) is reduced and correlates nega-
tively with the duration of progressive phase of MS. We conﬁrmed reduced expression of SOD1
and GSTP by MS-MSC along with reduced activity of SOD and GST and, to examine the antioxi-
dant capacity of MS-MSC under conditions of nitrosative stress, we established an in vitro cell
survival assay using nitric oxide-induced cell death. MS-MSC displayed differential susceptibility
to nitrosative stress with accelerated senescence and greater decline in expression of SOD1 and
GSTP in keeping with reduced expression of master regulators of antioxidant responses nuclear
factor erythroid 2-related factor 2 and peroxisome proliferator-activated receptor gamma coacti-
vator 1-α. Our results are compatible with dysregulation of antioxidant responses in MS-MSC
and have signiﬁcant implications for development of autologous MSC-based therapies for MS,
optimization of which may require that these functional deﬁcits are reversed. Furthermore,
improved understanding of the underlying mechanisms may yield novel insights into MS patho-
physiology and biomarker identiﬁcation. STEM CELLS TRANSLATIONAL MEDICINE
2018;00:1–11
SIGNIFICANCE STATEMENT
The potential of autologous mesenchymal stromal cell-based therapy for multiple sclerosis
(MS) and other neurological diseases is currently being explored in clinical trials although the
effects of disease on mesenchymal stromal cell phenotype and function have not been exten-
sively examined. We have demonstrated that mesenchymal stromal cells isolated from patients
with progressive MS have increased susceptibility to nitrosative stress and reduced expression,
activity, and secretion of key antioxidants. Our ﬁndings have important implications for the
development of autologous mesenchymal stromal cell therapy for MS but also for other condi-
tions in which mesenchymal stromal cell function has not been fully characterized. In addition,
the potential contribution of mesenchymal stromal cell dysfunction to the pathophysiology of
progressive MS and/or its comorbidities should be explored further.
INTRODUCTION
Reactive oxygen and nitrogen species
(ROS/RNS) are by-products of normal aerobic
metabolism and are involved in the complex
regulation of several signaling pathways includ-
ing cell proliferation, survival, and inﬂamma-
tion [1–9]. Imbalance between ROS/RNS and
antioxidant function results in oxidative/
nitrosative stress that contributes to pathology
in a range of clinical contexts including ageing
and multiple sclerosis (MS) [10–13].
MS is an inﬂammatory demyelinating and
neurodegenerative disease of the central ner-
vous system, and progressive forms of MS are
characterized by a relentless accumulation of
neurological disability over time for which
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need. Mesenchymal stromal cells (MSCs) have a range of prop-
erties of relevance to cell therapy for MS including anti-inﬂam-
matory, immunomodulatory, and antioxidant paracrine activity
[14]. Given the wealth of preclinical data demonstrating ame-
lioration of disease and their favorable safety proﬁle, there
has been rapid clinical translation of autologous MSC-based
cell therapy for MS [15]. However, studies have shown that
MSC function changes with age and chronic exposure to a pro-
inﬂammatory environment [9,16] and few data are available
regarding MSC function in MS.
We have recently demonstrated that MSC isolated from
patients with progressive MS (MS-MSC) have reduced ex vivo
proliferation and clonogenic potential, premature senescence,
and accelerated shortening of telomere terminal restriction
fragments [17]. We have also shown that the MS-MSC secre-
tome has reduced in vitro neuroprotective potential [18].
Recently, others have demonstrated abnormalities in MSC iso-
lated from patients with progressive supranuclear palsy (PSP)
[19]. These ﬁndings add to the growing body of literature doc-
umenting altered MSC function in disease states, and the role
of MSC in their pathogenesis, and/or development of associ-
ated comorbidities [20], is now under investigation in a range
of clinical contexts including ageing syndromes [21,22], meta-
bolic syndrome [23], diabetes [24,25], rheumatoid arthritis
[26], and systemic lupus erythematosus [27].
Given that nitrosative stress has been implicated in the
pathogenesis of ageing [10], neurodegeneration [2], and MS
[11,12], we sought to examine the antioxidant capacity of MS-
MSC and their susceptibility to nitric oxide-induced cell death as
determined by exposure to DETANONOate, a nitric oxide donor.
MATERIALS AND METHODS
Study Cohort
MSC were isolated with appropriate consent from bone mar-
row samples from individuals undergoing elective total hip
replacement surgery (control MSC [C-MSC]; UK Research Ethics
Committee [REC] 10/H102/69) and patients with progressive
MS (MS-MSC) participating in the ACTiMuS (Assessment of
Bone Marrow-Derived Cellular Therapy in Progressive Multiple
Sclerosis, NCT01815632, REC 12/SW/0358) trial [17]. The clini-
cal details of control and MS subjects (sex, age, classiﬁcation of
MS, duration of disease progression, and exposure to disease
modifying therapy [DMT]) are presented as Supporting Infor-
mation (Table S1) together with the inclusion and exclusion cri-
teria for the ACTiMuS trial (Supporting Information Table S2).
In summary, patients with either primary or secondary MS with
an Expanded Disability Status Scale [28] of 4–6 were eligible
for the study if they were systemically well despite a clear his-
tory of disease progression in the preceding year during which
time they must not have been on DMT for MS.
The control cohort were older; median age of control sub-
jects 58.5 years old (7 males and 7 females) and median age
of MS patients 53 years old (13 males and 16 females;
unpaired t test p = .003). There was no sex bias between the
cohorts (p = .772) and an independent effect attributable to
birth sex was not observed in analyses. The control cohort had
not been exposed to immunomodulatory therapy in the past.
None of the 13 patients with primary progressive MS had
been exposed to immunomodulatory therapy or DMT. Of
those with secondary progressive MS (n = 16), eight had previ-
ously been treated with DMT (50%), and in all cases, treat-
ment had been discontinued >1 year prior to collection of
marrow in keeping with the entry criteria for the ACTiMuS
trial. Not all samples were available for all experiments; the
number of biological replicates is speciﬁed in each experiment
individually and details regarding the cohort and which sam-
ples were used for each analysis are presented as Supporting
Information. There was no signiﬁcant association between age
and duration of disease progression in the MS cohort.
Although there were insufﬁcient patients with a history of
exposure to DMT included in the experiments to perform
regression analysis, there was no difference between the
cohorts with primary and secondary progressive disease in any
of the analyses.
Isolation of Bone Marrow-Derived MSC
MSC from control and MS marrow were isolated using density
gradient centrifugation and seeded in 25 cm2 ﬂasks (passage
0) with medium consisting of low glucose Dulbecco’s modiﬁed
Eagle’s medium (DMEM) (Sigma USA) with 10% foetal bovine
serum (FBS) selected for the growth of MSC (Gibco USA) and
1% Penicillin and Streptomycin (Sigma). At approximately 70%
conﬂuence, plastic-adherent cells were detached using 0.25%
trypsin (Sigma) and reseeded at 2.5 × 105 cells per 75 cm2
ﬂask (passage 1). To ensure isolated MSC conformed to inter-
national deﬁning criteria [29], cell surface phenotype and mes-
enchymal differentiation potential were examined as
previously reported [30]. For all experiments, both control
(C-MSC) and MS-MSC were matched for passage number
(either at passage 3 [p3] or passage 4 [p4]) to avoid potentially
confounding effects.
MSC-Conditioned Medium
Conﬂuent MSC cultures, at either p3 or p4, were washed twice
in DMEM and cultured for 24 hours in minimal medium (MIN),
consisting of DMEM without serum supplemented with 1%
insulin-free Sato (containing 100 μg/ml bovine serum albumin
[BSA], 100 μg/ml transferrin, 0.06 μg/ml progesterone,
16 μg/ml putrescine, 0.04 μg/ml selenite, 0.04 μg/ml thyrox-
ine, and 0.04 μg/ml triiodothryonine), 1% Penicillin and Strep-
tomycin, and 0.5% L-glutamine. Conditioned media (CM) was
collected, ﬁltered, and frozen at −80C for future experiments.
Proteomics
Protein was extracted from MSC using mirVana PARIS RNA
and protein puriﬁcation kit (Life Technologies USA), following
which samples were incubated on ice for 30 minutes and then
centrifuged at 10,000g for 10 minutes. The supernatant was
collected and stored at −80C. Protein content was determined
using the Qubit Fluorometer and Quant-iT Protein assay kit
(Invitrogen USA) according to manufacturer’s instructions and
diluted to 2 mg/ml.
Liquid chromatography-tandem mass spectrometry (LC-
MSMS) of C-MSC and MS-MSC conditioned medium was per-
formed by the University of Bristol Proteomics Facility using a
previously described protocol for tandem mass tagging (Thermo
Fisher Scientiﬁc USA) coupled to liquid chromatography-mass
spectrometry [31]. Values were normalized to a randomly
selected control.
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Enzyme-Linked Immunosorbent Assay
Ready to use sandwich enzyme-linked immunosorbent assay
(ELISA) assay for superoxide dismutase 1 (SOD1) (Affymetrix
USA) and Glutathione S-Transferase Pi 1 (GSTP1) (Cusabio USA)
were performed on 1:1 diluted CM from MS and control MSC
according to manufacturer’s instructions. A standard curve was
prepared, and absorbance read on a spectrophotometer at
450 nm. Values were interpolated into the curve and multiplied
by the dilution factor to obtain the ﬁnal concentration.
DETANONOate Toxicity Assay
Prior experiments have demonstrated a linear relationship
between methylthiazolyldiphenyl-tetrazolium bromide (MTT)
signal and MSC live cell number (data not shown). A stock
solution (50 mM in 10 mM NaOH) of (Z)-1-(2-([minoethyl]-N-
[2-ammonioethyl]amino)daizen-1-ium-1,2-diolate (DETANONOate;
Enzo Life Sciences UK) was prepared immediately before use.
Cells were seeded at 1 × 104 cells per well in a 96-well plate.
Postadherence, basal culture medium was removed and cells
washed in DMEM before addition of MIN or MIN with DETA-
NONOate at the relevant concentration for 24 hours. Subse-
quently, medium was removed and warm phosphate buffered
saline containing 10% FBS and 1 mg/ml of MTT added. After
incubation for 3 hours at 37C, the solution was aspirated and
plate left to dry before 50 μl per well dimethyl sulfoxide
(Sigma) was added and absorbance read at 570 nm following
dissolving of formazan. Optical density (OD) values from a sin-
gle patient were normalized to its own MIN value to allow
comparison between samples from different patients.
Bromodeoxyuridine Cell Proliferation Assay
MSC were seeded at 1 × 104 cells per well in a 96 well plate.
DETANONOate and bromodeoxyuridine (BrdU) (Millipore UK)
were added following cell adherence for 24 hours. Cells were
subsequently ﬁxed, washed, and incubated with anti-BrdU
monoclonal antibody for 1 hour according to manufacturer’s
instructions. After the addition of the peroxidase-conjugated
secondary antibody, substrate, and stop solution, the OD signal
was measured using a spectrophotometer with a wavelength
of 450 nm.
Senescence-Associated β-Galactosidase Staining
C-MSC and MS-MSC were seeded at 5 × 104 cells per 35 mm
wells, treated with DETANONOate 0.6 mM for 24 hours and
stained with the senescence-associated β-galactosidase (SA-
β-gal) kit (Cell Signaling Technology USA).
Immunoblotting
MSC (5 × 104 cells per well) were cultured in a 6-well plate for
5 days before exposure to 0.6 mM of DETANONOate. At set
time points (2, 6, and 24 hours), cells were washed and lysed
using universal lysis buffer (Millipore). A Qubit Fluorometer
and Quant-iT Protein assay kit (Invitrogen) were used accord-
ing to manufacturer’s instructions to ensure equal loading of
samples. Western blot and dot blot analysis were performed
as previously described [32]. In brief, protein lysates were
denatured at 95C and run on Tris-HCl 10%–20% ready gels
(Bio-Rad) for Western blot or diluted in Tris-buffered saline
(TBS, Biorad USA) and added to the Bio-Dot Microﬁltration
apparatus containing a prewet nitrocellulose membrane (Bio-
Rad). After transfer to nitrocellulose membrane and blocking
in 5% BSA (Sigma) or 5% of milk in TBS-Tween for 1 hour,
membranes were incubated overnight in primary antibody at
4C. Antibodies used were mouse anti-SOD1 (1:2,000, R&D
USA), mouse anti-GSTP1 (1:2,000; Santa Cruz USA), rabbit anti-
peroxisome proliferator-activated receptor-gamma coactivator-
1alpha (PGC1α) (1:3,000; Santa Cruz), rabbit anti-nuclear factor
erythroid 2-related factor 2 (Nrf2) (1:3,000; Santa Cruz), rabbit
anticatalase (1:5,000; Abcam UK), mouse anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (1:5,000; Abcam), and
antiactin (1:5,000; Abcam). Speciﬁc protein expression patterns
were visualized by chemiluminescence using ECL Plus Western
Blotting Detection System (Amersham USA). After developing,
the ChemiDoc MP Imager (Biorad), Image Lab software was
used to measure the integrated density. Values are expressed
relative to loading control proteins GAPDH or actin. Western
blots were used to conﬁrm antibody speciﬁcity and for base-
line comparison of protein expression between C-MSC and
MS-MSC. Given the number of replicates over multiple time
points, dot blots were used for determination of protein
expression in experiments using exposure to DETANONOate.
Real-Time Polymerase Chain Reaction
RNA was extracted and cDNA produced using the Taqman
gene expression cells-Ct-kit (Applied Biosystems USA) accord-
ing to the manufacturer’s instructions. RNA samples were
quantiﬁed using a Quant-iT™ RNA assay kit (Invitrogen)
according to manufacturer’s instructions to ensure equal load-
ing. Real-time polymerase chain reaction (RT-PCR) was per-
formed using the StepOnePlus Real-Time PCR System (Applied
Biosystems) with Assay-on-demand Gene Expression Products
for SOD1, GSTP1, PGC1α, Nrf2, and GAPDH (Taqman MGB
probe, FAM dye-labeled, Applied Biosystems) using 10 ng
cDNA in 20 μl of FAST master mix (Applied Biosystems). Reac-
tions were run at 50C for 2 minutes, 95C for 20 seconds,
40 cycles of 95C for 1 second, and 60C for 20 seconds. Sam-
ples were analyzed in triplicate. Relative gene expression (rela-
tive quantiﬁcation value) was calculated using the 2−ΔΔCt
method with GAPDH as reference (housekeeping) gene.
SOD and GST Activity Assay
SOD and GST activities were quantiﬁed in cell lysates using the
relevant colorimetric assay (Abcam) according to manufac-
turer’s protocol. OD was measured at 450 nm for SOD and
340 nm for GST in kinetic mode.
Statistical Analysis
All graphs were generated using GraphPad PRISM 5 (Graph Pad
Software USA), which was also used for statistical analyses (*)
other than those which used multiple regression (#). Where
stated, a regression model which allowed for correlation
between replicates isolated from the same individual (cluster
option) was used for multivariant analyses including, where rel-
evant, age, birth sex, presence of progressive MS, and time
(STATA v12, StataCorp) USA. Nonparametric bootstrap analysis
was used to estimate SE and conﬁdence intervals (CI) to
account for possible non-normality of the parameter’s distribu-
tion. Grouped analyses show mean  SEM, and regression lines
were ﬁtted with 95% CI. Analyses were two sided and values of
p < .05 considered statistically signiﬁcant. Where regression was
www.StemCellsTM.com © 2018 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
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used, only those analyses where the 95% CI did not include zero
were considered signiﬁcant.
RESULTS
Reduced Secretion of SOD1 and GSTP by MS-MSC
Associated with Duration of Progressive MS
Using LC-MSMS, SOD1, and GSTP1 were detected in the secre-
tome of C-MSC and MS-MSC but there was a relative reduc-
tion in the secretion of both antioxidants by MS-MSC (Fig. 1A,
1D). The results were conﬁrmed using ELISA; an independent
negative effect of the presence of progressive MS was seen on
secretion of both SOD1 and GSTP1 when the effect of age was
taken into consideration (Fig. 1B, 1E). Secretion of both SOD1
and GSTP1 correlated negatively with duration of the progres-
sive phase of MS (Fig. 1C, 1F). Catalase secretion was not
detected in the MSC secretome using LC-MSMS.
Reduced Expression of SOD1 and GSTP with Reduced
Activity of SOD and GST in MS-MSC
Immunoblotting was used to examine the expression of SOD1
and GSTP1 and demonstrated reduced expression in MS-MSC
when adjustment was made for the effect of age (Fig. 2A, 2B).
There was no difference in catalase expression (Fig. 2C), and
additional analyses of catalase activity were not therefore
undertaken. Antioxidant activity was assessed using activity
assays for total SOD and GST attributable to the lack of avail-
ability of an assay capable of differentiating between activity
of speciﬁc isoforms. Accounting for effects of age, MS-MSC
had reduced activity of both SOD (Fig. 2E) and GST (Fig. 2F).
MS-MSC have Increased In Vitro Susceptibility to
Nitrosative Stress
C-MSC was exposed to DETANONOate at varying concentrations
for 24 hours, and cell survival was determined using MTT assay.
Based on our previous experience with in vitro assays of cell toxic-
ity and survival, we selected the dose for subsequent cell survival
studies as that inducing approximately 33% cell death (0.6 mM
DETANONOate inducing 37% cell survival; data not shown).
C-MSC and MS-MSC were exposed to 0.6 mM DETANONO-
ate for 24 hours, and the effects on cell survival are compared.
MS-MSC displayed increased susceptibility to DETANONOate,
an effect sustained statistically when regression analysis was
undertaken to account for effect of age (Fig. 3A). No differ-
ences in MS-MSC survival were observed according to MS sub-
type (primary or secondary progressive disease) or duration of
progressive phase of the disease.
Despite the short duration of experiments, BrdU was used
to exclude the possibility that differences in cell survival
between populations of C-MSC and MS-MSC could be explained
by altered proliferation rate; no difference in MSC proliferation
Figure 1. Reduced MS-MSC secretion of SOD1 and GSTP1 in association with duration of progressive phase of MS. Analysis of the MSC
secretome was undertaken using LC-MSMS (C-MSC n = 4; MS-MSC n = 6) and ELISA (C-MSC n = 5; MS-MSC n = 11). (A): When the differ-
ence in age between the cohorts was accounted for, an independent, statistically signiﬁcant effect of the presence of MS was seen with
reduced secretion of SOD1 (regression analysis, #, p = .042, CI −0.093 to 3.9) as measured by LC-MSMS. (B): Reduced secretion of SOD1
by MS-MSC as determined by ELISA (regression analysis, ###, p < .001, CI −1.554 to −0.451). (C): SOD1 secretion by MS-MSC as deter-
mined by ELISA negatively correlated with duration of the progressive phase of MS (Pearson r −.789, p = .002, CI −0.938 to −0.392). (D):
Reduction in secretion of GSTP1 by MS-MSC as determined by LC-MSMS (regression analysis, #, p = .034, CI −0.975 to −0.039). (E): Reduc-
tion in GSTP1 in MS-MSC measured by ELISA (regression analysis, #, p = 0.04, CI −45.332 to −1.021). (F): Negative correlation of GSTP1 se-
cretion by MS-MSC with duration of progressive disease (Pearson r −.665, p = .036, CI −0.913 to −0.061). The data are the means  SEM
of multiple biological replicates as listed. Abbreviations: CI, conﬁdence interval; C-MSC, control mesenchymal stromal cells; ELISA,
enzyme-linked immunosorbent assay; GSTP1, Glutathione S-Transferase Pi 1; LC-MSMS, liquid chromatography-tandem mass spectrome-
try; MS, multiple sclerosis; MSC, mesenchymal stromal cells; MS-MSC, mesenchymal stromal cells from patients with multiple sclerosis;
SOD1, superoxide dismutase 1.
© 2018 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
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between MS and control cohorts was noted following exposure
of MSC to 6 mM DETANONOate for 24 hours (Fig. 3B).
DETANONOate Induces Accelerated Senescence in
MS-MSC
Increasing MSC donor age is known to increase senescence
[17], and multiple regression analysis was used in all
analyses of SA-β-gal expression. C-MSC and MS-MSC at p4
were treated with 0.6 mM DETANONOate for 24 hours fol-
lowing which the SA-β-gal assay was performed to quantify
senescent cells (blue staining). Very low levels of SA-β-gal
expression are seen following MSC exposure to MIN alone
for 24 hours (Fig. 4A, 4B). As expected, MSC SA-β-gal expres-
sion increased following DETANONOate exposure consistent
Figure 2. MSC expression and activity of antioxidants in standard culture conditions. Densitometric analysis of Western blots was used
to examine protein expression in standard culture conditions (C-MSC n = 3; MS-MSC n = 7). (A): SOD1 expression was reduced in MS-
MSC compared to C-MSC (regression analysis, ##, p = .002, CI −0.737 to −0.159). (B): GSTP1 expression was reduced in MS-MSC (regres-
sion analysis, ##, p = 0.006, CI −1.39 to −0.23). (C): Catalase expression was unaltered. (D): Representative bands are shown. (E): SOD
activity was reduced in MS-MSC (n = 4) compared to C-MSC (n = 4; regression analysis, ##, p = .003, CI −25.706 to −5.288). (F): GST activ-
ity was reduced in MS-MSC (n = 6) compared to C-MSC (n = 3; Mann Whitney test, *, p = .038; regression analysis, ##, p = .006, CI
−0.854 to −0.14). The data are the means  SEM of multiple biological replicates as listed. Abbreviations: CI, conﬁdence interval; C-MSC,
control mesenchymal stromal cells; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSTP1, Glutathione S-Transferase Pi 1; MS, mul-
tiple sclerosis; MSC, mesenchymal stromal cell; MS-MSC, mesenchymal stromal cells from patients with multiple sclerosis; SOD1, superox-
ide dismutase 1.
Figure 3. MS-MSC show increased susceptibility to DETANONOate in vitro. (A): MSC were exposed to 0.6 mM DETANONOate for
24 hours following which viability was measured using the MTT assay. Relative to C-MSC (n = 7), MS-MSC (n = 13) were more vulnerable
to DETANONOate-induced toxicity and a signiﬁcant effect was also seen when the potential confounding effect of age was taken into con-
sideration (Mann Whitney test, *, p < .05; regression analysis, #, p = .04, CI −0.801 to −0.016). (B): Difference in MTT signal cannot be
attributed to altered proliferation rates as changes in BrdU expression were not observed, including when age was accounted for (C-MSC
n = 3 and MS-MSC n = 3). The data are the means  SEM of multiple biological replicates as listed. Abbreviations: CI, conﬁdence interval;
BrdU, bromodeoxyuridine; C-MSC, control mesenchymal stromal cells; MS-MSC, mesenchymal stromal cells from patients with multiple
sclerosis; MTT, methylthiazolyldiphenyl-tetrazolium bromide.
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with an increase in number of senescent MSC (Fig. 4C–4E).
Senescent cells displayed expected phenotypical changes
including enlarged ﬂattened morphology, granular cytoplasm,
vacuoles and enlarged nuclei (Fig. 4C, 4D). Following DETA-
NONOate exposure, the proportion of senescent cells as
deﬁned by those expressing SA-β-gal was signiﬁcantly greater
in MS-MSC cultures compared with the proportion of senes-
cent C-MSC (Fig. 4E).
Reduced MS-MSC Expression of SOD1 and GSTP1
Following Exposure to Nitrosative Stress
Expression of SOD1 and GSTP1 under conditions of nitrosative
stress were examined following exposure of MSC to DETA-
NONOate for 24 hours as previously. SOD1 gene expression
increased after 24 hours of DETANONOate exposure and no
difference in response was seen between C-MSC and MS-MSC
(Fig. 5A). However, protein expression of SOD1 declined in
both C-MSC and MS-MSC with an earlier and greater decline
observed in MS-MSC (Fig. 5B). No signiﬁcant changes in GSTP1
gene expression were seen at any of the time points examined
in C-MSC or MS-MSC (Fig. 5C) although GSTP1 protein expres-
sion was lower in MS-MSC at 2 and 6 hours and, adjusting for
age, an independent, negative, statistically signiﬁcant effect of
the presence of MS on GSTP1 expression was observed
(Fig. 5D).
Reduced Nrf2 Expression in MS-MSC in Standard
Culture Conditions and Following Nitrosative Stress
The transcriptional factor Nrf2 is a key regulator of
antioxidant-enzyme genes, and we therefore explored
(i) whether MS-MSC have reduced expression of Nrf2 under
standard culture conditions and (ii) whether Nrf2 expression
increases in response to DETANONOate exposure. Western
blot analysis under standard culture conditions demonstrated
that MS-MSC express lower levels of Nrf2 compared to C-MSC
(Fig. 6A). Nrf2 gene expression was upregulated in both C-MSC
and MS-MSC over the 24-hour period following exposure to
DETANONOate (Fig. 6C). Following exposure of C-MSC to nitro-
sative stress, Nrf2 protein expression showed a trend toward
an increase in expression, particularly after 2 and 6 hours of
DETANONOate exposure (Fig. 6D). In contrast, MS-MSC expres-
sion of Nrf2 declined over the 24-hour period following expo-
sure to DETANONOate (Fig. 6D).
MS-MSC in Standard Culture Conditions and Following
Nitrosative Stress Have Reduced Expression of PGC1α
The master regulator of ROS-detoxifying enzymes PGC1α was
measured in MSC from both control subjects and patients with
MS under standard culture conditions and after 2, 6, and
24 hours of DETANONOate exposure. Protein expression of
PGC1α was signiﬁcantly decreased in MS-MSC compared to
C-MSC under standard culture conditions following adjustment
for age (Fig. 7A). At the time points examined after DETA-
NONOate treatment (2, 6, and 24 hours), there was no change
in PGC1α gene expression in either C-MSC or MS-MSC
(Fig. 7C). However, C-MSC and MS-MSC showed differing
responses to DETANONOate exposure in the level of PGC1α
protein expression with a reduction observed in MS-MSC
(Fig. 7D).
DISCUSSION
MSC have been identiﬁed as an excellent candidate for cell
therapy in a wide variety of clinical contexts. Increasingly, how-
ever, attention is being given to the quality of MSC used for
therapy, particularly autologous cells which have been exposed
to disease microenvironment. Detailed examination of MSC
isolated from donors with chronic diseases is yielding novel
insights into disease pathophysiology and in vivo MSC func-
tion. In this study, we have examined the susceptibility of MS-
MSC to nitrosative stress in vitro together with an analysis of
Figure 4. Increased susceptibility of MS-MSC to senescence following DETANONOate exposure. (A): C-MSC under standard culture con-
ditions show little or no expression of SA-β-gal (blue). (B): MS-MSC also have few SA-β-gal positive cells at low passage number under
standard culture conditions. (C): Following exposure to DETANONOate (0.6 mM for 24 hours), C-MSC show increased expression of SA-
β-gal at 5 days. (D): MS-MSC show disproportionally greater expression of SA-β-gal following DETANONOate exposure indicative of
increased senescence. (E): When effects of age are taken into consideration, MS-MSC show higher expression of SA-β-gal expression in
response to DETANONOate exposure (regression analysis, ###, p < .001, CI 13.125 to 36.184). The data are the means  SEM of multiple
biological replicates (C-MSC (n = 3) and MS-MSC (n = 4); Scale bar 100 μm. Abbreviations: CI, conﬁdence interval; C-MSC, control mesen-
chymal stromal cells; MIN, minimal medium; MS-MSC, mesenchymal stromal cells from patients with multiple sclerosis; SA-β-gal,
senescence-associated β-galactosidase.
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expression and activity of key antioxidants and their regulators
under basal cell culture conditions and in response to nitrosa-
tive stress.
We have demonstrated that nitrosative stress differentially
affects MS-MSC, inducing changes of accelerated senescence.
In basal cell culture conditions and following exposure to
nitrosative stress, MS-MSC have reduced levels of expression
of Nrf2 and PGC1α known regulators of the antioxidant
response. There is concomitant reduced expression of antioxi-
dants SOD1 and GSTP although catalase expression was unal-
tered. In vitro activity of SOD and GST was both reduced in
MS-MSC.
PGC1α has a key role in mitochondrial biogenesis, respira-
tion, and induction of antioxidant programs [33]. Reduced
expression in MS has been noted and is thought to contribute
to mitochondrial changes and neuronal loss [34]. PGC1α lacks
DNA-binding activity but interacts with and coactivates several
transcription factors including Nrf2, which controls constitutive
and inducible expression of an array of antioxidant enzymes
including SOD, GST, and catalase [35]. Downregulation of
PGC1α has been shown to affect the antioxidant response in
Friedreich’s ataxia [36] and expression of PGC1α has been
noted to be lower in adipose tissue-derived MSC from elderly
donors [37]. Interestingly, MSC isolated from patients with PSP
had ﬁvefold lower levels of expression of PGC1α compared
with control MSC [19] and, in an induced pluripotent stem cell
model of Parkinson’s disease, S-nitrosylation of the transcrip-
tion factor myocyte enhancer factor 2c (MEF2C) contributes to
mitochondrial dysfunction and apoptotic cell death via dysre-
gulation of the PGC1α-MEF2C transcriptional network [38], a
Figure 5. Reduced MS-MSC expression of SOD1 and GSTP1 under conditions of nitrosative stress. Following exposure to DETANONOate,
SOD1 and GSTP1 gene and protein expression relative to baseline were examined over a 24-hour period. (A): SOD1 expression, measured
by RT-PCR relative to GAPDH, increased over time with exposure to DETANONOate in both C-MSC and MS-MSC (regression analysis, ##,
p = .008, CI 0.002 to 0.016). There was no difference between SOD1 expression in C-MSC and MS-MSC at any time point examined. (B):
Protein expression of SOD1 in response to nitrostative stress in C-MSC and MS-MSC was examined using immunoblotting. Following
adjustment for age, SOD1 expression declined with exposure to DETANONOate (regression analysis, ###, p < .001, CI −0.027 to −0.019).
An independent, negative effect on SOD1 expression attributable to progressive MS was seen following adjustment for age (regression
analysis, p < .001, CI −0.515 to −0.226). (C): A signiﬁcant change in GSTP1 expression was not observed in either C-MSC or MS-MSC fol-
lowing exposure to DETANONOate including after correction for age. (D): Overall, GSTP1 protein expression following exposure to DETA-
NONOate fell in both C-MSC and MS-MSC and an independent negative effect of progressive MS was observed (regression analysis, ###,
p < .001, CI −0.47 to −0.326). The data are the means  SEM of multiple biological replicates C-MSC n = 3, MS-MSC n = 4. Abbreviations:
CI, conﬁdence interval; C-MSC, control mesenchymal stromal cells; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSTP1, Glutathi-
one S-Transferase Pi 1; MS, multiple sclerosis; MS-MSC, mesenchymal stromal cells from patients with multiple sclerosis; RT-PCR, real
time polymerase chain reaction; SOD1, superoxide dismutase 1.
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mechanism which may have contributed to the decrease in
PGC1α expression seen in MS-MSC at baseline and in response
to nitrosative stress.
Nrf2 is a regulator of cellular resistance to oxidative stress
with an integral role in controlling expression of antioxidant
response element-dependent genes. Nrf2 is known to be
Figure 6. Reduced Nrf2 expression in MS-MSC in standard culture conditions and in response to DETANONOate exposure. (A): Reduced
expression of Nrf2 in MS-MSC (n = 12) compared with C-MSC (n = 6) in standard culture conditions as determined by Western blot densi-
tometric analysis (Student’s t test * p = .04; regression analysis, ###, p < .001, CI −0.897 to −0.293). (B): Representative bands for Nrf2
and GAPDH are demonstrated. (C): Nrf2 expression in C-MSC and MS-MSC at baseline and following exposure to DETANONOate was
examined over a 24-hour period using RT-PCR and the fold difference relative to the average expression in cultures not exposed to DETA-
NONOate was calculated by the (2−ΔΔCT) method with GAPDH as the calibrator. Expression increased with time of exposure (C-MSC n = 3,
MS-MSC n = 4; regression analysis, ##, p = .007, CI −0.011 to −0.002) but, although expression of Nrf2 was lower in MS-MSC at all time
points examined, this did not reach statistical signiﬁcance. (D): Expression of Nrf2 by C-MSC (n = 3) and MS-MSC (n = 7) following expo-
sure to DETANONOate was examined using immunoblotting; overall, a negative effect of DETANONOate exposure on Nrf2 expression was
seen over time (regression analysis, ###, p < .0001, CI −0.024 to 0.0123) with an independent, negative effect of the presence of progres-
sive MS was seen following adjustments for age (regression analysis, p < .0001, CI −0.708 to −0.336). The data are the means  SEM of
multiple biological replicates as listed. Abbreviations: CI, conﬁdence interval; C-MSC, control mesenchymal stromal cells; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; MS, multiple sclerosis; MS-MSC, mesenchymal stromal cells from patients with multiple scle-
rosis; Nrf2, nuclear factor erythroid 2-related factor 2; RT-PCR, real-time polymerase chain reaction.
Figure 7. Reduced PGC1α expression in MS-MSC in standard culture conditions and in response to DETANONOate exposure. (A): Densi-
tometric analysis of Western blots demonstrated reduced PGC1α protein expression in MS-MSC (n = 12) compared to C-MSC (n = 6), and
this reached statistical signiﬁcance following adjustment for age (Student’s t test p = .09; regression analysis, ##, p = .009, CI −0.911 to
−0.127). (B): Representative bands for PGC1α and GAPDH are shown. (C): PGC1α gene expression following DETANONOate exposure rela-
tive to baseline expression was examined over a 24-hour period using RT-PCR in both C-MSC (n = 3) and MS-MSC (n = 4). Using GAPDH
as the calibrator, no change in PGC1α expression was seen in either C-MSC and MS-MSC, including when analysis was undertaken to
account for the effects of age. (D): Using immunoblotting, the change in PGC1α protein expression in response to DETANONOate expo-
sure was examined in C-MSC (n = 3) and MS-MSC (n = 7). Overall, reduced PGC1α expression with increasing time of exposure to DETA-
NONOate was observed (regression analysis, ###, p < .001, CI −0.482 to −0.042). An independent, negative effect of the presence of MS
was seen following adjustment for age (regression analysis, p = .027, CI −0.91 to 0.054). The data are the means  SEM of multiple bio-
logical replicates as listed. Abbreviations: CI, conﬁdence interval; C-MSC, control mesenchymal stromal cells; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; MS, multiple sclerosis; MS-MSC, mesenchymal stromal cells from patients with multiple sclerosis; PGC1α,
peroxisome proliferator-activated receptor-gamma coactivator-1alpha; RT-PCR, real time polymerase chain reaction.
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activated by nitrosative agents [39], and its repression has
been associated with ageing [35] including in a model of
Hutchinson-Gilford progeria syndrome where MSC attrition is
accelerated [40]. Nrf2 has been shown to maintain the self-
renewal potential of MSC [41], and overexpression induces
MSC proliferation and reduces apoptosis, including in response
to oxidative stress [42,43]. In models of MS, loss of Nrf2 has
been shown to exacerbate neurological deﬁcits [44,45] with
activation being protective [46]. Dimethyl fumarate, a disease
modifying agent for the treatment of MS, may act at least in
part via activation of the Nrf2 pathway [47,48].
The mechanism(s) underlying reduced expression of Nrf2
in MS-MSC in response to nitrostative stress has not been
identiﬁed to date. Regulation of Nrf2 is complex and
involves multiple pathways but a major factor is known to
be the variation in the level of protein stability; under basal
conditions, Nrf2 is rapidly degraded by the 26S proteasome,
and this allows for an immediate increase when ubiquityla-
tion and proteasomal degradation are inhibited by stimuli
including redox stress [49]. Low levels of Nrf2 in the
absence of environmental stressors have also been attrib-
uted to translational repression [50], suggesting that a possi-
ble alternative or additional mechanism for the failure to
increase Nrf2 expression in MS-MSC was failure to reverse
the translational repression of Nrf2 appropriate for basal
conditions. Indeed, we note that in experimental allergic
encephalitis as in our experiments, Nrf2 mRNA levels are
maintained but expression is reduced suggesting either
impaired translation or changes in post-translational proces-
sing [51].
We note the differences in age between the control and
MS cohorts and have used a multiple regression model to
account for this. There was no sex bias in the cohorts, and
an independent effect attributable to birth sex was not
observed in the regression analyses. In addition to age-
mismatch between cohorts, an additional potential confound-
ing factor is the difference in MSC source between patients
and control subjects, that is, marrow from the posterior iliac
crest and femoral head, respectively. However, pelvic marrow
is generally taken to be the gold standard for MSC isolation
[52] and while the indication for hip replacement in the con-
trol cohort could be a possible additional confounding factor,
MSC changes in the context of osteoarthritis have not been
consistently reported [53–56]. None of the control subjects
or those with primary progressive MS had exposure to immu-
nomodulatory drugs or DMT. We were unable to perform
regression analyses to determine if there was an independent
effect of prior exposure to DMT in the cohort with secondary
progressive MS attributable to the low numbers of patients
included in each analysis. However, there was no differential
effect of disease subtype on any of the analyses undertaken
and this, combined with the time interval between exposure
and marrow collection, would make it relatively unlikely that
our disease-speciﬁc results can be explained by DMT
exposure.
Our ﬁndings are consistent with a failure of homeostasis
in MS-MSC attributable to dysregulation of PGC1α and
Nrf2-mediated antioxidant responses, which in turn contrib-
ute to a phenotype of premature aging. We note that a sim-
ilar mechanism has been proposed in the context of vascular
oxidative stress associated with ageing [57]. The negative
association between antioxidant responses (SOD1 and
GSTP1 secretion) and duration of progressive MS raises the
possibility that chronic exposure to disease adversely affects
MSC function with functional consequences for the bone
marrow microenvironment including, for example, alterations
in regulatory and pro-inﬂammatory T-cell populations. While
this may, in turn, contribute to disease pathophysiology, the
ﬁnding adds to our previous work, demonstrating changes
consistent with accelerated ageing in MS bone marrow and
has clear implications for both MSC-based and autologous
haematopoietic stem cell therapy for MS and other condi-
tions where oxidative stress plays a role in disease [17]. It
would suggest that bone marrow-derived cell therapy is
more likely to be effective in MS patients with a shorter
phase of progressive disease although, based on currently
available data, we are unable to speculate regarding a cut-
off in terms of age or disease duration for consideration of
therapy.
Future work will include analyses of expression of addi-
tional Nrf2 and PGC1α target genes, examination of vascular
oxidative stress associated with MS, exploration of whether
reversal of the identiﬁed deﬁcits in antioxidant response of
MS-MSC improves the neuroprotective potential of MS-MSC,
and further analysis of bone marrow microenvironment and
function in MS.
CONCLUSION
We have demonstrated that MS-MSC have reduced expression
of Nrf2 and PGC1α under basal culture conditions with
reduced expression of key antioxidants SODs and GSTP and
reduced activity of SOD and GST. Furthermore, MS-MSC have
increased susceptibility to nitrosative stress which is associated
with reduced expression of Nrf2 and PGC1α. Our ﬁndings have
signiﬁcant implication for those developing autologous MSC-
based therapies for MS as identiﬁcation and correction of the
factors responsible are likely to be required if the full potential
of MSC for autologous cell-based treatment is to be realized.
Furthermore, we predict that understanding the mechanisms
involved will yield novel insights into the pathophysiology of
MS and aid identiﬁcation of new drug targets for the treat-
ment of progressive MS.
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